Prothena Corporation PLC header image

Prothena Corporation PLC

PRTA

Equity

ISIN IE00B91XRN20 / Valor 20224443

NASDAQ (2025-03-14)
USD 13.74-2.35%

Prothena Corporation PLC
UMushroom community rating:

star star star star star
4.00 1 votes No rating yet
NegativeNeutralPositive

About company

Prothena Corporation PLC is a biotechnology firm focused on the late-stage clinical development of treatments for neurodegenerative and rare peripheral amyloid diseases. Leveraging its expertise in protein dysregulation, the company has developed a diverse pipeline of investigational therapies aimed at addressing the complex challenges of neurological dysfunction and misfolded proteins. Prothena's approach combines internal discovery with strategic collaborations across academia and the industry to advance its portfolio of novel therapeutic solutions. Founded from the legacy of Athena Neurosciences and established as an independent entity in December 2012, Prothena trades on the Nasdaq Global Select Market under the symbol "PRTA." The company's commitment to innovation is rooted in its history of significant scientific contributions, including discoveries that have advanced the understanding of Alzheimer’s disease and the development of FDA-approved treatments for multiple sclerosis.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (10.01.2025):

Net Loss

For the third quarter of 2024, Prothena Corporation PLC reported a net loss of $59.0 million, compared to a net income of $21.9 million in the same quarter of 2023. For the first nine months of 2024, the net loss was $64.4 million, compared to a net loss of $79.6 million for the same period in 2023. The net loss per share was $1.10 for the third quarter and $1.20 for the first nine months of 2024.

Revenue

Prothena Corporation PLC reported total revenue of $1.0 million for the third quarter of 2024, a significant decrease from $84.9 million in the third quarter of 2023. For the first nine months of 2024, total revenue was $133.0 million, compared to $91.1 million for the same period in 2023. The revenue was primarily derived from collaboration revenue with Bristol Myers Squibb.

Research and Development Expenses

Research and development expenses for Prothena Corporation PLC totaled $50.7 million for the third quarter of 2024, down from $57.9 million in the same quarter of 2023. For the first nine months of 2024, R&D expenses were $172.3 million, up from $158.7 million for the same period in 2023. The changes were primarily due to variations in manufacturing and clinical trial expenses.

General and Administrative Expenses

General and administrative expenses for Prothena Corporation PLC were $16.8 million for the third quarter of 2024, slightly up from $16.6 million in the third quarter of 2023. For the first nine months of 2024, G&A expenses were $50.4 million, compared to $44.9 million for the same period in 2023. The increase was mainly due to higher personnel-related expenses.

Cash Position

As of September 30, 2024, Prothena Corporation PLC had $520.1 million in cash, cash equivalents, and restricted cash, with no debt. The company expects to end the year with approximately $468 million in cash, cash equivalents, and restricted cash, based on its financial guidance for 2024.

Summarized from source with an LLMView Source

Key figures

-48.1%1Y
-57.0%3Y
37.4%5Y

Performance

70.6%1Y
76.2%3Y
77.9%5Y

Volatility

Market cap

1744 M

Market cap (USD)

Daily traded volume (Shares)

431,420

Daily traded volume (Shares)

1 day high/low

15.25 / 14.66

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

1 votes
Performance:
starstarstarstarstar
3.00
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
4.00
Daniel Bruggmann
Switzerland, 05 Mar 2025
star star star star star
Für unsere Gesundheit

EQUITIES OF THE SAME SECTOR

Doximity Inc
Doximity Inc Doximity Inc Valor: 111921599
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.24%USD 63.38
HP Inc
HP Inc HP Inc Valor: 29968910
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%USD 28.41
argenx SE
argenx SE argenx SE Valor: 36542319
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.09%USD 604.96
The Descartes Systems Group Inc
The Descartes Systems Group Inc The Descartes Systems Group Inc Valor: 840184
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.71%CAD 142.80
Varonis Systems Inc
Varonis Systems Inc Varonis Systems Inc Valor: 22677089
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.17%USD 40.01
Zscaler Inc
Zscaler Inc Zscaler Inc Valor: 40562757
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.34%USD 197.81
AECOM
AECOM AECOM Valor: 2986443
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.10%USD 95.08
Cohu Inc
Cohu Inc Cohu Inc Valor: 919424
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.02%USD 17.03
PTC Inc
PTC Inc PTC Inc Valor: 20488241
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.63%USD 155.80
GRENKE AG
GRENKE AG GRENKE AG Valor: 28741392
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.14%EUR 13.92